A randomized, double-blind, placebo-controlled, dose-titration study to assess the safety, tolerability, and efficacy of C105 in persons with multiple sclerosis with cognitive impairment

Trial Profile

A randomized, double-blind, placebo-controlled, dose-titration study to assess the safety, tolerability, and efficacy of C105 in persons with multiple sclerosis with cognitive impairment

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2011

At a glance

  • Drugs Levafetamine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Sep 2011 Status changed from active, no longer recruiting to completed, according to publication of results.
    • 01 Sep 2011 Results published in the Multiple Sclerosis Journal.
    • 17 Dec 2008 Positive results announced by Cognition Pharmaceuticals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top